Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000437 · ClinicalTrials.gov registry record · Phase 4
Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)
A Phase 4 study, sponsored by The Scripps Research Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT00000437 is a Phase 4 study that has completed, run by The Scripps Research Institute. The registered enrollment target is 60 participants.
The verdict
NCT00000437, a Phase 4 study, has completed, sponsored by The Scripps Research Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness of naltrexone (Revia) or matched placebo combined with nicotine patch (Nicotrol) or placebo patch using a 2x2 design in reducing drinking and smoking in patients with both nicotine and alcohol dependence.
Interventions
- DRUG Naltrexone Tablet and Nicotine Patch
- DRUG Naltrexone Tablet and Placebo Patch
- DRUG Placebo Tablet and Nicotine Patch
- DRUG Placebo Tablet and Placebo Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 1997-09-26 |
| Est. Completion | 2005-09-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000437
The ClinicalTrials.gov registry entry for NCT00000437 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Scripps Research Institute, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Naltrexone Tablet and Nicotine Patch is the first listed.
NCT00000437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000437 about?
NCT00000437 is a clinical study titled "Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)". The purpose of this study is to determine the effectiveness of naltrexone (Revia) or matched placebo combined with nicotine patch (Nicotrol) or placebo patch using a 2x2 design in reducing drinking and smoking in patients with both nicotine and alcohol dependence.
What is the current status of trial NCT00000437?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 1997-09-26. Estimated completion is 2005-09-15.
What interventions are being tested in trial NCT00000437?
The interventions under investigation include: Naltrexone Tablet and Nicotine Patch (DRUG), Naltrexone Tablet and Placebo Patch (DRUG), Placebo Tablet and Nicotine Patch (DRUG), Placebo Tablet and Placebo Patch (DRUG).
Who is sponsoring clinical trial NCT00000437?
This trial is sponsored by The Scripps Research Institute, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.